| Literature DB >> 28700701 |
Elisa Morrone1, Cinzia Sguazzin2, Giorgio Bertolotti3, Andrea Giordano4, Alberto Braghiroli5, Gian Luigi Balestroni6, Raffaele Manni7, Luigi Ferini Strambi8, Vincenza Castronovo8, Marco Zucconi8, Fabrizio De Carli9, Eleonora Pinna2, Marcella Ottonello10, Ines Giorgi11, Michele Terzaghi7, Sara Marelli8, Francesco Fanfulla1.
Abstract
OBJECTIVES: The aim of this study was to develop and validate a questionnaire designed to measure the impact of sleep impairment on emotional distress in patients with various sleep disorders.Entities:
Mesh:
Year: 2017 PMID: 28700701 PMCID: PMC5507265 DOI: 10.1371/journal.pone.0180743
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Main characteristics of the sample enrolled.
| OSAS | INS | BSD | C HYPER | NORM | ||
|---|---|---|---|---|---|---|
| N° (% of total sample) | 267 (58.4) | 55 (12%) | 24 (5.2) | 11 (2.4) | 100 (21.9) | |
| age± sd | 52.4±13.6 | 46.9±16.9 | 53.9±17.2 | 41.5±20.1 | 41.2±15.6 | |
| BMI (Kg/m2) ± sd | 31.3±8 | 25.4±4.1 | 25.3±3.6 | 25.9±4.4 | 23.5±4.3 | |
| Male sex N (%) | 176 (65.9) | 25 (45.4) | 15 (62.5) | 15 (72.7) | 45 (45) | |
| less than 6 h | 111 (41.6) | 36 (65.4) | 16 (66.7) | 3 (27.3) | 16 (16) | |
| 6–8 h | 131 (49.1) | 10 (18.2) | 8 (33.3) | 5 (45.4) | 74 (74) | |
| 8–10 h | 13 (4.9) | 1 (1.8)) | 0 (0) | 3 (27.3) | 9 (9) | |
| do not know | 10 (3.7) | 6 (10.9) | 0 (0) | 0 (0) | 1 (1) | |
| NA | 2 (0.7) | 2 (3.6) | 0(0) | 0 (0) | 0 (0) | |
| Rested | 78 (29.2) | 3 (5.4) | 3 (12.5) | 5 (45.4) | 55 (55) | |
| Just rested | 125 (46.8) | 24 (43.6) | 9 (37.5) | 4 (36.7) | 33 (33) | |
| Tired | 60 (22.5) | 27 (49.1) | 12 (50) | 2 (18.9) | 11 (11) | |
| NA | 4 (1.5) | 1 (1.8) | 0 (0) | 0 (0) | 1 (0.9) |
Legend: OSAS = Obstructive Sleep Apnea Syndrome; INS = Insomnia; BSD = Behavioral Sleep disorders; NORM = Normal; C Hyper = Central Hypersomnia; BMI = body mass index; NA = not applicable.
Fig 1Analysis flow chart of the procedure for development and validation of the MaSQuDI-17.
Fig 2Parallel analysis—development phase–initial item sets.
Factor analysis: Varimax and Promax rotations in the 36-item questionnaire, 2 factors as per Parallel Analysis.
Single factor analysis for the reduced item set (17 items, Final version). Factor loadings < .3 omitted.
| 36 items | 17 Items | ||||
|---|---|---|---|---|---|
| VARIMAX Rotation | PROMAX Rotation | - | |||
| Item | |||||
| 1 | 0.401 | 0.371 | |||
| 2 | 0.347 | 0.325 | |||
| 3 | 0.652 | 0.619 | 0.671 | ||
| 4 | 0.314 | 0.305 | |||
| 5 | 0.639 | 0.594 | 0.664 | ||
| 6 | 0.614 | 0.615 | 0.736 | ||
| 7 | 0.818 | 0.789 | 0.830 | ||
| 8 | 0.68 | 0.638 | 0.671 | ||
| 9 | 0.587 | 0.594 | 0.729 | ||
| 10 | |||||
| 11 | 0.53 | 0.528 | |||
| 12 | 0.554 | 0.574 | 0.712 | ||
| 13 | 0.359 | 0.356 | |||
| 14 | 0.481 | 0.47 | |||
| 15 | 0.566 | 0.545 | |||
| 16 | 0.648 | 0.642 | 0.692 | ||
| 17 | 0.671 | 0.659 | 0.795 | ||
| 18 | 0.636 | 0.632 | |||
| 19 | 0.349 | 0.373 | |||
| 20 | 0.304 | 0.554 | |||
| 21 | 0.339 | 0.333 | |||
| 22 | 0.616 | 0.628 | |||
| 23 | 0.767 | 0.762 | 0.824 | ||
| 24 | 0.413 | 0.412 | 0.559 | ||
| 25 | 0.746 | 0.706 | |||
| 26 | 0.739 | 0.73 | |||
| 27 | 0.432 | 0.433 | |||
| 28 | 0.467 | 0.312 | 0.521 | 0.383 | 0.657 |
| 29 | |||||
| 30 | 0.525 | 0.533 | 0.649 | ||
| 31 | 0.308 | 0.552 | |||
| 32 | 0.609 | 0.59 | 0.678 | ||
| 33 | 0.767 | 0.742 | |||
| 34 | 0.322 | 0.352 | 0.500 | ||
| 35 | |||||
| 36 | 0.382 | 0.387 | |||
Fig 3Rasch analysis—persons item map.
(A) Starting version of 36 items. (B) Final item set, after recoding, 17 items.
Fig 4Category probability curves—development phase.
(A) Development phase for the 4-point Likert rating scale. (B) Development phase–for the 3-point Likert choice for the final 17-item set after recoding.
Rasch analysis–start and final item set FIT tables.
| Start | Final | |||||||
|---|---|---|---|---|---|---|---|---|
| Item | MEASURE | S.E. | INFIT MNSQ | OUTFIT MNSQ | MEASURE | S.E. | INFIT MNSQ | OUTFIT MNSQ |
| 1 | -0.87 | 0.06 | 1.17 | 1.14 | ||||
| 2 | -0.21 | 0.07 | 1.31 | 1.27 | ||||
| 3 | -0.42 | 0.07 | 0.93 | 0.90 | -0.06 | 0.09 | 1.04 | 1.06 |
| 4 | 0.85 | 0.10 | 1.47 | 1.38 | ||||
| 5 | -0.93 | 0.06 | 0.96 | 0.92 | -0.77 | 0.09 | 1.09 | 1.17 |
| 6 | -0.30 | 0.07 | 0.86 | 0.80 | 0.06 | 0.09 | 0.93 | 0.89 |
| 7 | -0.79 | 0.07 | 0.58 | 0.58 | -0.70 | 0.10 | 0.74 | 0.73 |
| 8 | -0.81 | 0.06 | 0.80 | 0.79 | -0.71 | 0.09 | 1.04 | 1.08 |
| 9 | -0.27 | 0.07 | 0.88 | 0.87 | 0.14 | 0.09 | 0.92 | 0.97 |
| 10 | -1.70 | 0.07 | 1.89 | 2.12 | ||||
| 11 | 0.84 | 0.10 | 1.20 | 1.26 | ||||
| 12 | 0.70 | 0.09 | 1.06 | 0.84 | 1.31 | 0.10 | 0.92 | 0.81 |
| 13 | 0.65 | 0.09 | 1.49 | 1.55 | ||||
| 14 | 0.15 | 0.08 | 1.36 | 1.26 | ||||
| 15 | 0.72 | 0.09 | 1.12 | 1.11 | ||||
| 16 | -0.28 | 0.07 | 0.77 | 0.75 | 0.13 | 0.09 | 0.98 | 0.94 |
| 17 | -1.10 | 0.06 | 0.56 | 0.56 | -1.33 | 0.10 | 0.81 | 0.80 |
| 18 | 1.73 | 0.14 | 1.16 | 1.00 | ||||
| 19 | -0.65 | 0.07 | 0.79 | 0.81 | ||||
| 20 | 0.37 | 0.08 | 1.04 | 0.97 | 1.03 | 0.10 | 1.16 | 1.25 |
| 21 | 1.12 | 0.11 | 1.53 | 1.64 | ||||
| 22 | 0.98 | 0.10 | 1.25 | 1.14 | ||||
| 23 | -0.96 | 0.06 | 0.48 | 0.49 | -1.08 | 0.10 | 0.76 | 0.74 |
| 24 | -0.16 | 0.07 | 1.02 | 0.98 | 0.32 | 0.09 | 1.20 | 1.24 |
| 25 | 1.07 | 0.11 | 1.20 | 1.13 | ||||
| 26 | -0.53 | 0.07 | 0.59 | 0.58 | ||||
| 27 | 0.20 | 0.08 | 1.05 | 0.94 | ||||
| 28 | 0.38 | 0.08 | 0.88 | 0.81 | 1.01 | 0.10 | 0.99 | 1.04 |
| 29 | -0.57 | 0.07 | 1.29 | 1.41 | ||||
| 30 | -0.31 | 0.07 | 0.82 | 0.80 | 0.09 | 0.09 | 1.02 | 1.02 |
| 31 | -0.63 | 0.07 | 1.06 | 1.11 | -0.38 | 0.09 | 1.24 | 1.22 |
| 32 | -0.40 | 0.07 | 1.07 | 0.99 | 0.00 | 0.09 | 1.09 | 1.08 |
| 33 | 2.80 | 0.24 | 1.81 | 1.08 | ||||
| 34 | 0.27 | 0.08 | 1.29 | 1.15 | 0.93 | 0.10 | 1.22 | 1.16 |
| 35 | -0.85 | 0.06 | 1.07 | 1.09 | ||||
| 36 | -0.07 | 0.07 | 1.09 | 1.02 | ||||
Fig 5Parallel analysis—development phase—final item sets.
Fig 6Concurrent validity of the MaSQuDI–17scores according to subjective sleep duration and perceived restfulness at wake up.
Fig 7Box plot showing the distribution of mean scores and percentile for subjects suffering from Obstructive Sleep Apnea Syndrome, Insomnia, Behavioral Sleep Disorders and Central Hypersomnia.